Matthew Barth相关文献与解析，生知库 | 链接生命科学的每一步

Management of SIADH-related hyponatremia due to psychotropic medications - An expert consensus from the Association of Medicine and Psychiatry

精神药物引起的抗利尿激素分泌异常综合征（SIADH）相关低钠血症的管理——医学与精神病学协会专家共识

doi:10.1016/j.jpsychores.2021.110654

Pinkhasov, Aaron; Xiong, Glen; Bourgeois, James A; Heinrich, Thomas W; Huang, Heather; Coriolan, Shanice; Annamalai, Aniyizhai; Mangal, Jed P; Frankel, Steven; Lang, Michael; Raj, Y Pritham; Dandois, Matthew; Barth, Kelly; Stewart, Anne Louise; Rado, Jeffrey; Pesek, Justin; Sanders, Aaron; Spearman-McCarthy, E Vanessa; Gagliardi, Jane; Fiedorowicz, Jess G

免疫/内分泌

发表日期：2021

文献求助收藏

Novel cytokine-antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma

新型细胞因子抗体融合蛋白 N-820，可增强体外扩增的自然杀伤细胞对抗伯基特淋巴瘤的功能

期刊:Journal for ImmunoTherapy of Cancer

影响因子:10.3

doi:10.1136/jitc-2020-001238

Yaya Chu, Gaurav Nayyar, Nang Kham Su, Jeremy M Rosenblum, Patrick Soon-Shiong, John Lee, Jeffrey T Safrit, Matthew Barth, Dean Lee, Mitchell S Cairo

Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Induces Apoptosis and Augments Efficacy of Chemotherapy and Small Molecule Inhibitors in Pre-clinical Models of Diffuse Large B-cell Lymphoma

Pevonedistat 是一种 NEDD8 活化酶抑制剂，可诱导细胞凋亡并增强弥漫性大 B 细胞淋巴瘤临床前模型中化疗和小分子抑制剂的疗效

期刊:eJHaem

影响因子:

doi:10.1002/jha2.2

Pallawi Torka, Cory Mavis, Shalin Kothari, Sarah Belliotti, Juan Gu, Suchitra Sundaram, Matthew Barth, Francisco J Hernandez-Ilizaliturri

Development and reliability assessment of a new quality appraisal tool for cross-sectional studies using biomarker data (BIOCROSS)

利用生物标志物数据进行横断面研究的新型质量评价工具（BIOCROSS）的开发和可靠性评估

期刊:BMC Medical Research Methodology

影响因子:3.4

doi:10.1186/s12874-018-0583-x

Wirsching, Jan; Graßmann, Sophie; Eichelmann, Fabian; Harms, Laura Malin; Schenk, Matthew; Barth, Eva; Berndzen, Alide; Olalekan, Moses; Sarmini, Leen; Zuberer, Hedwig; Aleksandrova, Krasimira

发表日期：2018

文献求助收藏

Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model

伊布替尼显著抑制了布鲁顿酪氨酸激酶 (BTK) 磷酸化、体外增殖，并在临床前伯基特淋巴瘤 (BL) 模型中提高了总体生存率

期刊:Oncoimmunology

影响因子:

doi:10.1080/2162402X.2018.1512455

Yaya Chu, Sanghoon Lee, Tishi Shah, Changhong Yin, Matthew Barth, Rodney R Miles, Janet Ayello, Erin Morris, Lauren Harrison, Carmella Van de Ven, Paul Galardy, Stanton C Goldman, Megan S Lim, Michelle Hermiston, Linda M McAllister-Lucas, Lisa Giulino-Roth, Sherrie L Perkins, Mitchell S Cairo

Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development

己糖激酶 II 的上调导致利妥昔单抗化疗耐药，是治疗开发的临床相关靶点

期刊:Oncotarget

影响因子:

doi:10.18632/oncotarget.23425

Juan J Gu, Anil Singh, Kai Xue, Cory Mavis, Matthew Barth, Vivek Yanamadala, Peter Lenz, Michael Grau, Georg Lenz, Myron S Czuczman, Francisco J Hernandez-Ilizaliturri

信号转导

发表日期：2017

文献求助收藏

AMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas

AMG176 是一种 MCL-1 抑制剂，在侵袭性 B 细胞淋巴瘤的临床前模型中有效

Management of SIADH-related hyponatremia due to psychotropic medications - An expert consensus from the Association of Medicine and Psychiatry

精神药物引起的抗利尿激素分泌异常综合征（SIADH）相关低钠血症的管理——医学与精神病学协会专家共识

Novel cytokine-antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma

新型细胞因子抗体融合蛋白 N-820，可增强体外扩增的自然杀伤细胞对抗伯基特淋巴瘤的功能

Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Induces Apoptosis and Augments Efficacy of Chemotherapy and Small Molecule Inhibitors in Pre-clinical Models of Diffuse Large B-cell Lymphoma

Pevonedistat 是一种 NEDD8 活化酶抑制剂，可诱导细胞凋亡并增强弥漫性大 B 细胞淋巴瘤临床前模型中化疗和小分子抑制剂的疗效

Development and reliability assessment of a new quality appraisal tool for cross-sectional studies using biomarker data (BIOCROSS)

利用生物标志物数据进行横断面研究的新型质量评价工具（BIOCROSS）的开发和可靠性评估

Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model

伊布替尼显著抑制了布鲁顿酪氨酸激酶 (BTK) 磷酸化、体外增殖，并在临床前伯基特淋巴瘤 (BL) 模型中提高了总体生存率

Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development

己糖激酶 II 的上调导致利妥昔单抗化疗耐药，是治疗开发的临床相关靶点